Alzamend Financial Statements From 2010 to 2025

ALZN Stock  USD 1.15  0.03  2.68%   
Alzamend Neuro financial statements provide useful quarterly and yearly information to potential Alzamend Neuro investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Alzamend Neuro financial statements helps investors assess Alzamend Neuro's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Alzamend Neuro's valuation are summarized below:
Market Capitalization
6.2 M
Earnings Share
(138.31)
We have found one hundred twenty available fundamental signals for Alzamend Neuro, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate Alzamend Neuro's prevailing fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road.
Check Alzamend Neuro financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alzamend Neuro's main balance sheet or income statement drivers, such as Interest Expense of 11 K, Interest Income of 0.0 or Depreciation And Amortization of 43.4 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Alzamend financial statements analysis is a perfect complement when working with Alzamend Neuro Valuation or Volatility modules.
  
Check out the analysis of Alzamend Neuro Correlation against competitors.
To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.

Alzamend Neuro Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Current Liabilities3.9 M3.7 M1.4 M
Slightly volatile
Accounts Payable3.5 M3.4 M1.1 M
Slightly volatile
Net Receivables13.9 K14.6 K63.1 K
Very volatile
Deferred Long Term Liabilities60 K67.5 K73.6 K
Slightly volatile
Total Current Assets497.4 K523.5 K1.9 M
Slightly volatile
Common Stock75.3879.354.2 K
Very volatile
Total Assets690 K726.3 K2.5 M
Pretty Stable
Short and Long Term Debt Total174.9 K345.8 K109.9 K
Slightly volatile
Other Current Liabilities3.9 M3.7 M908.8 K
Slightly volatile
Cash410.8 K432.5 K1.4 M
Slightly volatile
Cash And Short Term Investments410.8 K432.5 K1.4 M
Slightly volatile
Common Stock Total Equity8.5 K11.1 K7.3 K
Slightly volatile
Common Stock Shares Outstanding578.5 K608.9 K3.8 M
Slightly volatile
Liabilities And Stockholders Equity690 K726.3 K2.5 M
Pretty Stable
Other Current Assets67.7 K71.3 K872.7 K
Slightly volatile
Other Stockholder Equity46.7 M59.1 M33.9 M
Slightly volatile
Total Liabilities1.9 M3.7 M1.6 M
Slightly volatile
Capital Stock59.062.15.6 K
Slightly volatile
Short Term Debt174.9 K345.8 K109.9 K
Slightly volatile
Capital Surpluse56.1 M71.3 M42.5 M
Slightly volatile
Short and Long Term Debt254.4 K270.6 K319.7 K
Slightly volatile
Preferred Stock Total Equity60.067.573.5938
Slightly volatile
Property Plant Equipment73.1 K71.9 K96.2 K
Slightly volatile

Alzamend Neuro Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization43.4 K45.7 K323 K
Pretty Stable
Selling General Administrative4.6 M3.7 M2.8 M
Slightly volatile
Other Operating Expenses9.4 M11.4 MM
Slightly volatile
Research Development4.6 M7.4 M4.2 M
Slightly volatile
Total Operating Expenses9.4 M11.4 MM
Slightly volatile
Non Operating Income Net Other3.4 K3.6 K44.1 K
Slightly volatile
Selling And Marketing Expenses369.4 K284.4 K116 K
Slightly volatile
Cost Of Revenue40.6 K58.4 K28.1 K
Slightly volatile

Alzamend Neuro Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Total Cash From Financing Activities4.7 M4.2 M3.2 M
Slightly volatile
Change To Netincome2.5 M4.1 M1.7 M
Slightly volatile
End Period Cash Flow410.8 K432.5 K1.7 M
Pretty Stable
Stock Based CompensationM1.1 M1.2 M
Slightly volatile
Begin Period Cash FlowM5.9 M2.3 M
Slightly volatile
Depreciation38.2 K58.4 K20.8 K
Slightly volatile
Other Non Cash Items6106431.4 M
Slightly volatile
Issuance Of Capital Stock5.7 M3.9 M2.6 M
Slightly volatile
Sale Purchase Of Stock1711801.8 M
Slightly volatile
Cash Flows Other Operating514.5 K577.8 K637.6 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables2.7 M2.6 M924.8 K
Slightly volatile
Capex To Depreciation3.173.3423.2671
Slightly volatile
Payables Turnover0.01020.01560.0092
Slightly volatile
Cash Per Share0.480.52.4045
Slightly volatile
Days Payables Outstanding36.6 K24.2 K42 K
Slightly volatile
Income Quality0.810.960.6077
Slightly volatile
Current Ratio0.150.162.9591
Very volatile
Graham Number25.7332.0821.7277
Slightly volatile
Capex Per Share0.160.20.1844
Slightly volatile
Interest Debt Per Share0.640.530.3709
Pretty Stable
Debt To Assets0.950.550.5078
Very volatile
Days Of Payables Outstanding36.6 K24.2 K42 K
Slightly volatile
Ebt Per Ebit1.111.151.0241
Slightly volatile
Quick Ratio0.150.162.9602
Very volatile
Net Income Per E B T0.810.90.9825
Slightly volatile
Cash Ratio0.09970.11.3947
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio0.820.920.998
Slightly volatile
Debt Ratio0.950.550.5078
Very volatile

Alzamend Neuro Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Enterprise Value702.2 M865.6 M845 M
Slightly volatile

Alzamend Fundamental Market Drivers

Cash And Short Term Investments376 K

Alzamend Upcoming Events

21st of March 2024
Upcoming Quarterly Report
View
31st of January 2024
Next Fiscal Quarter End
View

About Alzamend Neuro Financial Statements

Alzamend Neuro investors utilize fundamental indicators, such as revenue or net income, to predict how Alzamend Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-2.9 M-2.8 M
Cost Of Revenue58.4 K40.6 K

Pair Trading with Alzamend Neuro

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alzamend Neuro position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alzamend Neuro will appreciate offsetting losses from the drop in the long position's value.

Moving together with Alzamend Stock

  0.82JNJ Johnson JohnsonPairCorr

Moving against Alzamend Stock

  0.63MLAB Mesa Laboratories Earnings Call This WeekPairCorr
  0.58BMY Bristol Myers Squibb Earnings Call This WeekPairCorr
  0.41GILD Gilead Sciences Earnings Call This WeekPairCorr
  0.34MDGL Madrigal PharmaceuticalsPairCorr
The ability to find closely correlated positions to Alzamend Neuro could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alzamend Neuro when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alzamend Neuro - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alzamend Neuro to buy it.
The correlation of Alzamend Neuro is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alzamend Neuro moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alzamend Neuro moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alzamend Neuro can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Alzamend Neuro offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alzamend Neuro's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alzamend Neuro Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alzamend Neuro Stock:
Check out the analysis of Alzamend Neuro Correlation against competitors.
To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.
You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alzamend Neuro. If investors know Alzamend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alzamend Neuro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(138.31)
Return On Assets
(2.14)
Return On Equity
(44.08)
The market value of Alzamend Neuro is measured differently than its book value, which is the value of Alzamend that is recorded on the company's balance sheet. Investors also form their own opinion of Alzamend Neuro's value that differs from its market value or its book value, called intrinsic value, which is Alzamend Neuro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alzamend Neuro's market value can be influenced by many factors that don't directly affect Alzamend Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alzamend Neuro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alzamend Neuro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alzamend Neuro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.